laurent Castera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5609603/publications.pdf

Version: 2024-02-01

19657 14208 21,577 133 61 128 citations h-index g-index papers 144 144 144 16205 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 2005, 128, 343-350.	1.3	2,216
2	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	3.7	2,171
3	Non-invasive evaluation of liver fibrosis using transient elastography. Journal of Hepatology, 2008, 48, 835-847.	3.7	1,170
4	Pitfalls of liver stiffness measurement: A 5-year prospective study of 13,369 examinations. Hepatology, 2010, 51, NA-NA.	7.3	890
5	Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2019, 156, 1264-1281.e4.	1.3	882
6	WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 1: Basic Principles and Terminology. Ultrasound in Medicine and Biology, 2015, 41, 1126-1147.	1.5	718
7	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. Journal of Hepatology, 2021, 75, 659-689.	3.7	676
8	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall in Der Medizin, 2017, 38, e16-e47.	1.5	659
9	WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver. Ultrasound in Medicine and Biology, 2015, 41, 1161-1179.	1.5	620
10	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2017, 18, 1624-1636.	10.7	595
11	Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C. Gastroenterology, 2012, 142, 1293-1302.e4.	1.3	533
12	Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology, 2006, 44, 1511-1517.	7.3	454
13	WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 2: Breast. Ultrasound in Medicine and Biology, 2015, 41, 1148-1160.	1.5	368
14	Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. Ultrasound in Medicine and Biology, 2018, 44, 2419-2440.	1.5	357
15	Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: Comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. Journal of Hepatology, 2009, 50, 59-68.	3.7	340
16	Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. European Journal of Gastroenterology and Hepatology, 2006, 18, 411-412.	1.6	331
17	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	17.8	330
18	Assessment of biopsyâ€proven liver fibrosis by twoâ€dimensional shear wave elastography: An individual patient dataâ€based metaâ€analysis. Hepatology, 2018, 67, 260-272.	7.3	322

#	Article	IF	Citations
19	Non invasive evaluation of portal hypertension using transient elastography. Journal of Hepatology, 2012, 56, 696-703.	3.7	289
20	Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterology, 2007, 7, 40.	2.0	268
21	Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology, 2016, 63, 138-147.	7.3	253
22	Noninvasive evaluation of NAFLD. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 666-675.	17.8	238
23	Pain experienced during percutaneous liver biopsy. Hepatology, 1999, 30, 1529-1530.	7.3	234
24	Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. Journal of Hepatology, 2015, 62, 848-854.	3.7	228
25	Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages. Clinical Chemistry, 2007, 53, 1615-1622.	3.2	227
26	Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. European Journal of Human Genetics, 2014, 22, 1305-1313.	2.8	217
27	Liver Stiffness Measurement in Children Using FibroScan: Feasibility Study and Comparison With Fibrotest, Aspartate Transaminase to Platelets Ratio Index, and Liver Biopsy. Journal of Pediatric Gastroenterology and Nutrition, 2007, 45, 443-450.	1.8	215
28	Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology, 2018, 286, 738-763.	7.3	215
29	Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology, 2009, 49, 1083-1089.	7.3	201
30	Critical comparison of elastography methods to assess chronic liver disease. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 402-411.	17.8	198
31	Prospective Comparison of Spleen and Liver Stiffness by Using Shear-Wave and Transient Elastography for Detection of Portal Hypertension in Cirrhosis. Radiology, 2015, 275, 589-598.	7.3	190
32	Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. Journal of Hepatology, 2010, 52, 191-198.	3.7	188
33	Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?. Gut, 2010, 59, 861-866.	12.1	182
34	SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology, 2009, 49, 1821-1827.	7.3	151
35	Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. Journal of Viral Hepatitis, 2009, 16, 300-314.	2.0	146
36	Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified) Tj ETQq0 0 C Hepatocellular Carcinoma Treated With Sorafenib. Oncologist, 2014, 19, 394-402.) rgBT /Ove 3.7	erlock 10 Tf 50 134

Hepatocellular Carcinoma Treated With Sorafenib. Oncologist, 2014, 19, 394-402.

#	Article	IF	CITATIONS
37	FibroScan (Vibration-Controlled Transient Elastography): Where Does It Stand in the United States Practice. Clinical Gastroenterology and Hepatology, 2015, 13, 27-36.	4.4	133
38	Screening for liver fibrosis in the general population: a call for action. The Lancet Gastroenterology and Hepatology, 2016, 1, 256-260.	8.1	131
39	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology, 2018, 67, 2001-2012.	7.3	125
40	Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study. Journal of Hepatology, 2010, 53, 630-638.	3.7	123
41	Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 291-303.	2.4	119
42	Non-invasive assessment of liver fibrosis: are we ready?. Lancet, The, 2010, 375, 1419-1420.	13.7	118
43	Relationship of Tumor Radiation–absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with ⁹⁰ Y in the SARAH Study. Radiology, 2020, 296, 673-684.	7.3	117
44	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. Journal of Hepatology, 2021, 74, 1109-1116.	3.7	112
45	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology, 2022, 75, 219-228.	7.3	107
46	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. Journal of Hepatology, 2019, 71, 1141-1151.	3.7	104
47	Assessment of portal hypertension and high-risk oesophageal varices with liver and spleen three-dimensional multifrequency MR elastography in liver cirrhosis. European Radiology, 2014, 24, 1394-402.	4.5	103
48	Non-invasive diagnosis of hepatic steatosis. Hepatology International, 2017, 11, 70-78.	4.2	101
49	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version). Ultraschall in Der Medizin, 2017, 38, 377-394.	1.5	93
50	Update on ultrasound imaging of liver fibrosis. Journal of Hepatology, 2013, 59, 180-182.	3.7	87
51	Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: Time for new guidelines?. Journal of Hepatology, 2007, 46, 528-529.	3.7	84
52	Mechanistic signatures of HPV insertions in cervical carcinomas. Npj Genomic Medicine, 2016, 1, 16004.	3.8	80
53	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. Clinical Gastroenterology and Hepatology, 2022, 20, 2567-2576.e6.	4.4	80
54	Impact of non-invasive biomarkers on hepatology practice: Past, present and future. Journal of Hepatology, 2022, 76, 1362-1378.	3.7	78

#	Article	IF	CITATIONS
55	Detecting splicing patterns in genes involved in hereditary breast and ovarian cancer. European Journal of Human Genetics, 2017, 25, 1147-1154.	2.8	76
56	Disease burden and economic impact of diagnosed nonâ€alcoholic steatohepatitis in five European countries in 2018: A costâ€ofâ€illness analysis. Liver International, 2021, 41, 1227-1242.	3.9	76
57	Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatology International, 2011, 5, 625-634.	4.2	7 2
58	Hepatitis C Virus-Induced Hepatocellular Steatosis. American Journal of Gastroenterology, 2005, 100, 711-715.	0.4	70
59	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2015, 35, 291-303.	3.6	65
60	Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. European Radiology, 2020, 30, 2293-2301.	4.5	65
61	Diagnosis of nonâ€alcoholic fatty liver disease/nonâ€alcoholic steatohepatitis: Nonâ€invasive tests are enough. Liver International, 2018, 38, 67-70.	3.9	64
62	Validation and Comparison of Simple Noninvasive Indexes for Predicting Liver Fibrosis in HIV-HCV-Coinfected Patients: ANRS CO3 Aquitaine Cohort. American Journal of Gastroenterology, 2008, 103, 1973-1980.	0.4	63
63	Landscape of pathogenic variations inÂa panel of 34 genes and cancer risk estimation from 5131 HBOC families. Genetics in Medicine, 2018, 20, 1677-1686.	2.4	62
64	Nonâ€invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics. Liver International, 2020, 40, 77-81.	3.9	58
65	How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?. Liver International, 2011, 31, 13-17.	3.9	56
66	Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. Journal of Hepatology, 2000, 32, 412-418.	3.7	55
67	Patient-Administered Nitrous Oxide/Oxygen Inhalation Provides Safe and Effective Analgesia for Percutaneous Liver Biopsy: A Randomized Placebo-Controlled Trial. American Journal of Gastroenterology, 2001, 96, 1553-1557.	0.4	50
68	Hepatitis B: are nonâ€invasive markers of liver fibrosis reliable?. Liver International, 2014, 34, 91-96.	3.9	50
69	Diagnosis of Liver Fibrosis: Present and Future. Seminars in Liver Disease, 2015, 35, 166-183.	3. 6	49
70	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, e1456-e1468.	4.4	49
71	Ultrasonic Adaptive Sound Speed Estimation for the Diagnosis and Quantification of Hepatic Steatosis: A Pilot Study. Ultraschall in Der Medizin, 2019, 40, 722-733.	1.5	48
72	When the Spleen Gets Tough, the Varices Get Going. Gastroenterology, 2013, 144, 19-22.	1.3	46

#	Article	IF	Citations
73	Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antiviral Therapy, 2009, 14, 187-193.	1.0	46
74	Patient-administered nitrous oxide/oxygen inhalation provides safe and effective analgesia for percutaneous liver biopsy: A randomized placebo-controlled trial. American Journal of Gastroenterology, 2001, 96, 1553-1557.	0.4	44
75	FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology, 2006, 43, 373-374.	7.3	44
76	Characterization of fortuitously discovered focal liver lesions: additional information provided by shearwave elastography. European Radiology, 2015, 25, 346-358.	4.5	44
77	Noninvasive Assessment of Liver Fibrosis. Digestive Diseases, 2015, 33, 498-503.	1.9	44
78	Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology, 2002, 35, 978-979.	7.3	43
79	Liver Stiffness by Transient Elastography to Detect Portoâ€Sinusoidal Vascular Liver Disease With Portal Hypertension. Hepatology, 2021, 74, 364-378.	7.3	40
80	Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers. European Journal of Human Genetics, 2017, 25, 1345-1353.	2.8	39
81	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. Gut, 2022, 71, 402-414.	12.1	39
82	Influence of heat stress on human monocyte-derived dendritic cell functions with immunotherapeutic potential for antitumor vaccines. Journal of Leukocyte Biology, 2007, 81, 1179-1187.	3.3	38
83	Radioembolisation with yttriumâ€'90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials, 2014, 15, 474.	1.6	38
84	Ultrasonic fat fraction quantification using <i>in vivo</i> adaptive sound speed estimation. Physics in Medicine and Biology, 2018, 63, 215013.	3.0	38
85	Assessing liver fibrosis. Expert Review of Gastroenterology and Hepatology, 2008, 2, 541-552.	3.0	37
86	EMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients. Human Mutation, 2011, 32, 325-334.	2.5	35
87	Genetic profiles of cervical tumors by highâ€throughput sequencing for personalized medical care. Cancer Medicine, 2015, 4, 1484-1493.	2.8	35
88	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data metaâ€analysis. Liver International, 2020, 40, 1435-1446.	3.9	35
89	Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. Liver Transplantation, 2016, 22, 1491-1500.	2.4	31
90	A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis. Clinical Cancer Research, 2017, 23, 2750-2758.	7.0	31

#	Article	IF	CITATIONS
91	Psychosocial Factors Associated With Perceived Disease Severity in Patients With Chronic Hepatitis C: Relationship With Information Sources and Attentional Coping Styles. Psychosomatics, 2005, 46, 25-33.	2.5	30
92	Prevalence of and Factors Associated With Hepatic Steatosis in Patients Coinfected With Hepatitis C Virus and HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 168-173.	2.1	28
93	Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: Long-term follow-up of 196 patients (4535 patient-years). Journal of Hepatology, 2007, 46, 19-25.	3.7	27
94	TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver International, 2015, 35, 2466-2473.	3.9	24
95	Full in-frame exon 3 skipping of <i>BRCA2</i> confers high risk of breast and/or ovarian cancer. Oncotarget, 2018, 9, 17334-17348.	1.8	24
96	OutLyzer: software for extracting low-allele-frequency tumor mutations from sequencing background noise in clinical practice. Oncotarget, 2016, 7, 79485-79493.	1.8	19
97	Apoptosisâ€related mitochondrial dysfunction defines human monocyteâ€derived dendritic cells with impaired immunoâ€stimulatory capacities. Journal of Cellular and Molecular Medicine, 2009, 13, 1321-1335.	3.6	18
98	Histologic and noninvasive estimates of liver fibrosis. Clinical Liver Disease, 2015, 6, 5-8.	2.1	16
99	Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates. JHEP Reports, 2021, 3, 100381.	4.9	15
100	Non-invasive tests for liver fibrosis progression and regression. Journal of Hepatology, 2016, 64, 232-233.	3.7	13
101	Liver stiffness and hepatocellular carcinoma: Liaisons dangereuses?. Hepatology, 2009, 49, 1793-1794.	7.3	12
102	Biomarkers in Liver Disease: Emerging Methods and Potential Applications. International Journal of Hepatology, 2012, 2012, 1-4.	1.1	9
103	Epidemiological and phylogenetic evidence for patient-to-patient hepatitis C virus transmission during sclerotherapy of varicose veins. Journal of Medical Virology, 2005, 76, 279-284.	5.0	8
104	Screening the general population for cirrhosis using transient elastography: finding a needle in a haystack?. Gut, 2011, 60, 883-884.	12.1	8
105	Assessing liver disease in HIV–HCV coinfected patients. Current Opinion in HIV and AIDS, 2015, 10, 316-322.	3.8	8
106	Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?. Journal of Hepatology, 2017, 66, 304-312.	3.7	8
107	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. European Journal of Gastroenterology and Hepatology, 2020, 32, 998-1007.	1.6	8
108	Biological response under treatment and prognostic value of protein induced by vitamin K absence or antagonist-II in a French cohort of patients with hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2020, 32, 1364-1372.	1.6	8

#	Article	IF	CITATIONS
109	Prospective external validation of a new nonâ€invasive test for the diagnosis of nonâ€ilcoholic steatohepatitis in patients with type 2 diabetes. Alimentary Pharmacology and Therapeutics, 2021, 54, 952-966.	3.7	8
110	Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD. European Radiology, 2022, 32, 1781-1791.	4.5	8
111	HEPACOM: multicenter, observational prospective study of outcome and monitoring of HCV positive antiviral-naÃ-ve patients managed in the French health care system. Gastroenterologie Clinique Et Biologique, 2007, 31, 1074-1080.	0.9	7
112	Noninvasive Algorithms for the Case Finding of "At-Risk―Patients with NAFLD. Seminars in Liver Disease, 2022, 42, 313-326.	3.6	7
113	Reply:. Hepatology, 2007, 46, 282-283.	7.3	5
114	Reply to "Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno's VI consensus― Journal of Hepatology, 2015, 63, 1049-1050.	3.7	5
115	Is it really worth adapting liver stiffness cutâ€offs according to <scp>AST</scp> levels?. Liver International, 2015, 35, 2495-2497.	3.9	4
116	Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C. MedGenMed: Medscape General Medicine, 2005, 7, 39.	0.2	3
117	Interpreting liver stiffness in the cirrhotic range: What are we measuring?. Journal of Hepatology, 2009, 50, 424-425.	3.7	2
118	Acoustic radiation force impulse imaging: a new technology for the noninvasive assessment of liver fibrosis?. Journal of Gastrointestinal and Liver Diseases, 2009, 18, 411-2.	0.9	2
119	Diagnosing cirrhosis non-invasively: Sense the stiffness but don't forget the nodules!. Journal of Hepatology, 2010, 52, 786-787.	3.7	1
120	Liver Stiffness by Ultrasound Elastography. , 2018, , 95-111.		1
121	Non-invasive Fibrosis Testing in Patients with Chronic Hepatitis B. Current Hepatology Reports, 2018, 17, 492-501.	0.9	1
122	Non-invasive diagnosis and follow-up of portal hypertension. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101767.	1.5	1
123	Screening for liver fibrosis in primary care: Focus on subjects above 40 and with metabolic risk factors. United European Gastroenterology Journal, 2021, 9, 889-891.	3.8	1
124	2D-shear wave elastography: number of acquisitions can be reduced according to clinical setting. Insights Into Imaging, 2021, 12, 145.	3.4	1
125	Transient elastography vs. blood tests for the diagnosis of cirrhosis: An empiric victory. Journal of Hepatology, 2009, 51, 229.	3.7	0
126	We will not rest on our laurels!. Journal of Hepatology, 2016, 64, 8-9.	3.7	0

#	Article	IF	CITATIONS
127	Screening studies of transient elastography and FibroTest in the general population – Authors' reply. The Lancet Gastroenterology and Hepatology, 2017, 2, 246-247.	8.1	O
128	Farewell from the EASL Secretary General. Journal of Hepatology, 2017, 66, 873-874.	3.7	0
129	BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer. Familial Cancer, 2017, 16, 167-171.	1.9	0
130	Assessment of Liver Disease Severity. , 2021, , 1-20.		0
131	Elastography Methods to Assess Chronic Liver Diseases: A Critical Comparison. , 2021, , 143-158.		0
132	Impact psychologique de l'annonce du diagnostic d'hépatite chronique C. , 2009, , 65-71.		0
133	Liver Diseases, Noninvasive Diagnosis and Staging of. , 2020, , 429-435.		0